By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
CapitalatorCapitalator
Notification Show More
Latest News
Better Buy: Upstart Holdings vs. LendingClub
May 22, 2022
Manufacturers Getting To Grips With Airless Tyres
May 22, 2022
Coinbase Has Gotten Crushed — Is It Time to Buy?
May 22, 2022
Some Jif peanut butter products are being recalled for possible salmonella contamination
May 22, 2022
Bangkok Votes For New Governor For First Time In Decade
May 22, 2022
Aa
  • NewsLive
  • Business
  • Politics
  • Investing
  • Finance
  • Companies
  • Markets
  • Crypto
  • Careers
  • Climate
  • Life
  • Tech
  • Videos
Reading: Why Intra-Cellular Therapies Trounced the S&P 500 Today
Share
CapitalatorCapitalator
Aa
  • News
  • Business
  • Politics
  • Markets
  • Crypto
  • Companies
  • Finance
  • Investing
  • Careers
  • Climate
  • Lifestyle
  • Tech
  • Videos
Search
  • Categories
  • Bookmarks
    • Customize Interests
    • My Bookmarks
  • More Foxiz
    • Blog Index
    • Sitemap
Have an existing account? Sign In
Follow US
Capitalator > Markets > Why Intra-Cellular Therapies Trounced the S&P 500 Today
Markets

Why Intra-Cellular Therapies Trounced the S&P 500 Today

Alexander Müller
Alexander Müller May 10, 2022
Updated 2022/05/10 at 11:01 PM
Share
SHARE

What happened

Even on an earnings season day when a clutch of companies notched earnings beats, Intra-Cellular Therapies‘ (ITCI 23.81%) first-quarter beat was notably impressive. Investors liked what they saw in the company’s freshly published earnings report, and they traded the stock up by nearly 24%. That absolutely crushed the 0.3% gain of the bellwether S&P 500 index on the day.

Contents
What happenedSo whatNow what

So what

For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year. Nearly all ($34.8 million) of the former tally derived from the net product revenue of Caplyta, the company’s bipolar depression treatment.

Caplyta is a relatively new drug on the market, having won Food and Drug Administration (FDA) approval last December.

Intra-Cellular has had to ramp up its commercialization efforts in order to sell the product, which is typical with recently marketed medications.  Consequently, the company’s selling, general, and administrative (SG&A) costs rose notably over the one-year stretch, to $75.5 million from the year-ago quarter’s 52.6 million.

These higher expenses filtered down into the bottom line. Intra-Cellular’s net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021’s $52.7 million deficit. 

However, analysts — and likely investors — had been bracing for worse. Prognosticators following the biotech stock were collectively modeling less than $33.7 million on the top line and a far deeper net loss of $0.92 per share.

Now what

It’ll be business as usual for Intra-Cellular going forward. Given the successful development of Caplyta, this is obviously fine with investors. 

The company quoted CEO Sharon Mates as saying that it is

confident in our ability to deliver continued strong growth and to improve the lives of patients. We continue to advance our pipeline, including our lumateperone programs in major depressive disorder (MDD) and mixed features.

 

Alexander Müller May 10, 2022
Share this Article
Facebook TwitterEmail Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

You Might Also Like

Markets

Better Buy: Upstart Holdings vs. LendingClub

May 22, 2022
Markets

Coinbase Has Gotten Crushed — Is It Time to Buy?

May 22, 2022
Markets

Want $1,000 in Passive Income? Invest $3,750 in These 3 Stocks and Wait 5 Years

May 22, 2022
Markets

Forget a Million-Dollar Retirement — Focus on This Instead

May 22, 2022

Capitalator

  • Business
  • Careers
  • Climate
  • Crypto
  • Finance
  • Investing
  • Markets
  • Technology

© 2022 Capitalator. All Rights Reserved.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?